Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
A November 2025 study found that GLP-1 receptor antagonist (RA) use, including semaglutide, was associated with reduced rates of urinary retention and urinary tract infections (UTIs) in non-diabetic women receiving treatment for overactive bladder syndrome
With rising obesity rates and a growing population of metabolic disease patients, China is widely expected to become one of the most important future growth markets for GLP-1 therapies
Programme length varies depending on individual objectives, physician recommendations, and overall treatment planning
Zhang, Yixiang, et al
The clinical trials revealed that participants achieved reduced overall body weight and an improved cardiometabolic health such as blood pressure and lipid profile
